Bristol OTC Stock Financials

BMYMP -  USA Stock  

USD 1,419  313.22  28.32%

Understanding current and past Bristol Myer Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Bristol Myer's financial statements are interrelated, with each one affecting the others. For example, an increase in Bristol Myer's assets may result in an increase in income on the income statement. Because of this, it is necessary to analyze all of Bristol Myer's financials over time to get the whole picture.
.
We suggest to use Bristol Myer Squi fundamental analysis to see if markets are presently mispricing the company. Put another way, you can use it to find out if Bristol Myer Squi is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We have collected data for twenty-six available fundamental indicators for Bristol Myer Squi, which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Bristol Myer Squi financials, including its cash per share, and the relationship between the revenue and cash flow from operations . Given that Bristol Myer Squi has a price to book of 117.91 X, we suggest you to validate Bristol Myer Squi prevailing market performance to make sure the company can sustain itself down the road. Use Bristol Myer to enhance returns of your portfolios. The stock experiences a very speculative upward sentiment. The trend is possibly hyped up. Check odds of Bristol Myer to be traded at $1774.03 in 90 days.

Bristol Fundamentals 

 
Refresh
With this module, you can analyze Bristol financials for your investing period. You should be able to track the changes in Bristol Myer individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Chance Of Financial Distress
Less than 46
Bristol Myer Squi has less than 46 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Bristol Myer otc stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Bristol Myer's official financial statements usually reflect Bristol Myer's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Bristol Myer Squi. For example, before you start analyzing numbers published by Bristol accountants, it's critical to develop an understanding of what Bristol Myer's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Bristol Myer's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bristol Myer's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Bristol Myer's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bristol Myer Squi. Please utilize our Beneish M Score to check the likelihood of Bristol Myer's management to manipulate its earnings.

Bristol Myer Company Summary

Bristol Myer competes with Oasis Petroleum, 3M, General Electric, Disney, and Boeing. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug Manufacturers - Major classification in USA and is traded on OTC Market. It employs 23700 people.
InstrumentUSA OTC Stock View All
ExchangeOTC Exchange
Business Address345 Park Avenue
SectorHealthcare
IndustryDrug Manufacturers - Major
BenchmarkDOW
Websitewww.bms.com
Phone212 546 4000
CurrencyUSD - US Dollar
You should never invest in Bristol Myer without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Bristol OTC Stock, because this is throwing your money away. Analyzing the key information contained in Bristol Myer's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Bristol Myer Key Financial Ratios

Generally speaking, Bristol Myer's financial ratios allow both analysts and investors to convert raw data from Bristol Myer's financial statements into concise, actionable information that can be used to evaluate the performance of Bristol Myer over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Bristol Myer Squi reports annually and quarterly.

Bristol Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Bristol Myer's current stock value. Our valuation model uses many indicators to compare Bristol Myer value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bristol Myer competition to find correlations between indicators driving Bristol Myer's intrinsic value. More Info.
Bristol Myer Squi is number one stock in cash and equivalents category among related companies. It is number one stock in ebitda category among related companies totaling about  0.98  of EBITDA per Cash and Equivalents. The ratio of Cash and Equivalents to EBITDA for Bristol Myer Squi is roughly  1.02 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bristol Myer by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bristol Myer's OTC Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bristol Myer's earnings, one of the primary drivers of an investment's value.

Bristol Myer Squi Systematic Risk

Bristol Myer's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Bristol Myer volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Bristol Myer Squi correlated with the market. If Beta is less than 0 Bristol Myer generally moves in the opposite direction as compared to the market. If Bristol Myer Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Bristol Myer Squi is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Bristol Myer is generally in the same direction as the market. If Beta > 1 Bristol Myer moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

About Bristol Myer Financials

What exactly are Bristol Myer Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Bristol Myer's income statement, its balance sheet, and the statement of cash flows. Potential Bristol Myer investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Bristol Myer investors may use each financial statement separately, they are all related. The changes in Bristol Myer's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bristol Myer's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines that you should keep in mind when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase year after year due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt to equity ratio because this number will tell you how much risk it has. If a company such as Bristol Myer is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to try and figure out if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that net revenue of Bristol grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only grown by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Bristol Myer January 28, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Bristol Myer help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bristol Myer Squi. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bristol Myer Squi based on widely used predictive technical indicators. In general, we focus on analyzing Bristol OTC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bristol Myer's daily price indicators and compare them against related drivers.
Information Ratio0.1022
Maximum Drawdown133.18
Value At Risk(7.36)
Potential Upside28.32
Continue to Trending Equities. Note that the Bristol Myer Squi information on this page should be used as a complementary analysis to other Bristol Myer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Valuation module to check real value of public entities based on technical and fundamental data.

Complementary Tools for Bristol OTC Stock analysis

When running Bristol Myer Squi price analysis, check to measure Bristol Myer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myer is operating at the current time. Most of Bristol Myer's value examination focuses on studying past and present price action to predict the probability of Bristol Myer's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bristol Myer's price. Additionally, you may evaluate how the addition of Bristol Myer to your portfolios can decrease your overall portfolio volatility.
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Is Bristol Myer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myer. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bristol Myer Squi is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myer's value that differs from its market value or its book value, called intrinsic value, which is Bristol Myer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myer's market value can be influenced by many factors that don't directly affect Bristol Myer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myer's value and its price as these two are different measures arrived at by different means. Investors typically determine Bristol Myer value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.